JPRN-UMIN000007353招募中2 期
A phase II neoadjuvant trial of concurrent trastuzumab and aromatase inhibitor in postmenopausal women with HER2-positive and hormone receptor-positive breast cancer. - A phase II neoadjuvant trial of concurrent trastuzumab and aromatase inhibitor in postmenopausal women with HER2-positive and hormone receptor-positive breast cancer.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 90years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Inflammatory breast cancer 2. Other active malignancies 3. History of cardiac infarction, valvular diseases of the heart and severe cardiac disfunction 4. Other medical conditions that could limit a patient's ability to undertake study therapy
研究者
相似试验
招募中
不适用
A phase II neoadjuvant trial of concurrent trastuzumab, paclitaxel and endocrine therapy in women with HER2-positive and hormone receptor-positive breast cancer.JPRN-UMIN000009108Keio University School of Medicine50
进行中（未招募）
不适用
Phase II Study of neoadjuvant therapy with trastuzumab plus docetaxel followed by trastuzumab plus pegylated liposomal doxorubicin and cyclophosphamide in human ErbB-2-positive operable or locally advanced breast cancer - CETRAOperable breast cancer patients or locally advanced breast cancer patients (stage II-III), with HER2 overexpression or gene amplificationMedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2006-003993-85-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
进行中（未招募）
1 期
A phase 2 clinical trial conducted investigate the effectiveness of trastuzumab deruxtecan (T-DXd) administered before surgery for the treatment of HER-2 positive breast cancer.HER2-positive breast cancer.MedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-002485-32-IECancer Trials Ireland80
招募中
3 期
A Phase 3 Trial of Neoadjuvant T-DXd Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)HER2-positive early breast cancerJPRN-jRCT2041210097Inoguchi Akihiro900
进行中（未招募）
3 期
Global open label phase-III study having 3 treatment arm in neoadjuvant setting in Patients with High-risk HER 2-positive Early-stage Breast CancerCTRI/2022/01/039210ASTRAZENECA AB